Immediate Effects of Intravenous Iron Therapy in Patients With Systolic Heart Failure and Iron Deficiency as Evaluated by Cardiac Magnetic Resonance Imaging: An Observational Prospective Study
The aim of this study is to observe the effect of intravenous ferric derisomaltose in participants with non-ischaemic heart failure (LVEF\<40%), iron deficiency (TSATS\<20%) and established on heart failure therapy including Sodium-glucose cotransporter 2 inhibitors (SGLT2i). Participants will undergo baseline laboratory blood tests, cardiac magnetic resonance imaging (cMRI), six-minute walk test, musculoskeletal function test and Kansas City Cardiomyopathy Questionnaire (KCCQ). These investigations will be repeated at 24 hours and 30 days after the administration of intravenous ferric derisomaltose.
• Participants capable of giving informed consent.
• Aged 18yrs and above.
• Diagnosed with heart failure and a reduction of their ejection fraction \< 40% by any modality.
• Non ischaemic cardiomyopathy as determined by baseline cardiac magnetic resonance imaging.
• Iron deficient per this definition: Transferrin saturations \< 20%.
• Established on Heart failure therapy including SGLT2i therapy for a minimum of four weeks prior to recruitment.
• New York Heart Association score of I - III class.